.jpeg)
Cabotegravir Sodium (Vocabria): Complete Guide to HIV Long-Acting Treatment and Prevention
1. Drug Overview
Cabotegravir sodium, brand name Vocabria, is an integrase strand transfer inhibitor (INSTI) primarily used for treating human immunodeficiency virus (HIV) infection. Developed by ViiV Healthcare, this medication is a key component of HIV long-acting treatment regimens.
2. Mechanism of Action
Cabotegravir sodium belongs to the HIV integrase inhibitor class. It works by inhibiting HIV integrase activity, preventing HIV RNA from reverse transcribing into DNA and integrating into the host cell genome, thereby suppressing viral replication. The drug is active against HIV-1, with limited activity against HIV-2.
3. Main Indications
Approved indications for cabotegravir sodium include: combination with other antiretroviral drugs for treating adult patients with HIV-1 infection; as part of long-acting treatment regimens for virologically suppressed adult patients; and pre-exposure prevention (PrEP) for high-risk populations.
4. Domestic Market Availability
Cabotegravir sodium is available in the domestic market. Pricing information should be obtained from local medical institutions. Specific prices vary by region, specification, and procurement channel.
5. International Market Pricing
In overseas markets, the European original cabotegravir sodium is priced at approximately 10,000 RMB. Specific prices are affected by region, specification, and procurement channels.
6. Long-Acting Treatment Regimen
A key feature of cabotegravir sodium is its use in long-acting HIV treatment. When combined with rilpivirine, it enables once-monthly or once-every-two-months dosing. This long-acting regimen is particularly suitable for patients with poor adherence or difficulty taking daily medication.
7. Dosage and Administration
Oral Lead-in Treatment
First, oral cabotegravir sodium and rilpivirine for approximately 4 weeks to assess tolerance.
Long-Acting Injection
After the oral lead-in period, begin intramuscular injection. The recommended dose is 600mg per administration (when used with rilpivirine). Specific regimens should follow medical advice.
8. Safety Analysis
Common Adverse Reactions
Common adverse reactions include injection site reactions, headache, fever, and rash. Most adverse reactions are mild to moderate.
Serious Adverse Reactions
Serious adverse reactions may include hypersensitivity reactions and liver function abnormalities.
Monitoring Requirements
Regular monitoring of liver function and HIV viral load is required during use.
9. Special Population Use
Hepatic Impairment
Cabotegravir sodium should be used with caution in patients with hepatic impairment. It is not recommended for patients with severe hepatic impairment.
Pregnancy and Lactation
Safety data for use in pregnant and breastfeeding women is limited. Benefits and risks should be carefully weighed.
10. Drug Interactions
Cabotegravir sodium is primarily metabolized by the liver and may interact with certain medications. Concomitant use with potent CYP3A4 inducers (such as rifampin, carbamazepine) may reduce blood drug concentrations.
11. Importance of Adherence
Whether using oral or long-acting injection regimens, patients must strictly follow the medication plan. Missed doses or treatment interruption may lead to virologic failure and development of resistance.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
